Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

ABSTRACT:

Background

Right-sided heart failure is the leading cause of death in pulmonary arterial hypertension (PAH). Similar to left heart failure, sympathetic overactivation and β-adrenoreceptor (βAR) abnormalities are found in PAH. Based on successful therapy of left heart failure with β-blockade, the safety and benefits of the nonselective β-blocker/vasodilator carvedilol were evaluated in PAH.

Methods

PAH Treatment with Carvedilol for Heart Failure (PAHTCH) is a single-center, double-blind, randomized, controlled trial. Following 1-week run-in, 30 participants were randomized to 1 of 3 arms for 24 weeks: placebo, low-fixed-dose, or dose-escalating carvedilol. Outcomes included clinical measures and mechanistic biomarkers.

Results

Decreases in heart rate and blood pressure

SUBMITTER: Farha S 

PROVIDER: S-EPMC5621927 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature